These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 31486040)

  • 1. Evaluation of Oncolytic Virus-Induced Therapeutic Tumor Vaccination Effects in Murine Tumor Models.
    Veinalde R
    Methods Mol Biol; 2020; 2058():213-227. PubMed ID: 31486040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of Tumor Antigen-Specific T-Cell Responses After Oncolytic Vaccination.
    Pol JG; Bridle BW; Lichty BD
    Methods Mol Biol; 2020; 2058():191-211. PubMed ID: 31486039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 5. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
    Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
    Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
    Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
    Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-7-loaded oncolytic adenovirus improves CAR-T cell therapy for glioblastoma.
    Huang J; Zheng M; Zhang Z; Tang X; Chen Y; Peng A; Peng X; Tong A; Zhou L
    Cancer Immunol Immunother; 2021 Sep; 70(9):2453-2465. PubMed ID: 33543339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-36γ-armed oncolytic virus exerts superior efficacy through induction of potent adaptive antitumor immunity.
    Yang M; Giehl E; Feng C; Feist M; Chen H; Dai E; Liu Z; Ma C; Ravindranathan R; Bartlett DL; Lu B; Guo ZS
    Cancer Immunol Immunother; 2021 Sep; 70(9):2467-2481. PubMed ID: 33538860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arming oncolytic viruses to leverage antitumor immunity.
    de Gruijl TD; Janssen AB; van Beusechem VW
    Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.
    Delaunay T; Achard C; Grégoire M; Tangy F; Boisgerault N; Fonteneau JF
    Methods Mol Biol; 2020; 2058():127-132. PubMed ID: 31486035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Oncolytic Adenovirus Targeting Transforming Growth Factor β Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy.
    Yang Y; Xu W; Peng D; Wang H; Zhang X; Wang H; Xiao F; Zhu Y; Ji Y; Gulukota K; Helseth DL; Mangold KA; Sullivan M; Kaul K; Wang E; Prabhakar BS; Li J; Wu X; Wang L; Seth P
    Hum Gene Ther; 2019 Sep; 30(9):1117-1132. PubMed ID: 31126191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.
    Granot T; Yamanashi Y; Meruelo D
    Mol Ther; 2014 Jan; 22(1):112-22. PubMed ID: 24025748
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
    Front Immunol; 2021; 12():610042. PubMed ID: 33679747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-Induced MHC I Ligands Shape Neo-Antitumor CD8 T Cell Responses during Oncolytic Virus-Based Cancer Immunotherapy.
    Murphy JP; Kim Y; Clements DR; Konda P; Schuster H; Kowalewski DJ; Paulo JA; Cohen AM; Stevanovic S; Gygi SP; Gujar S
    J Proteome Res; 2019 Jun; 18(6):2666-2675. PubMed ID: 31095916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.